“ We emphasize starting with a strong scientific foundation, focusing on innovative targets that address critical unmet medical needs. We aim to bring our first and subsequent… ”
In Conversation
“ The regulatory environment in China, guided by the NMPA, appears to be evolving positively, providing a conducive framework for pharmaceutical innovation and growth ”
“ We've strived for a culture rooted in fairness, transparency, and hard work ”
“ We recognize the substantial unmet medical needs in China and the growing potential of local innovation to drive global advancements ”
“ We are a global CDMO committed to delivering exceptional value and quality to our clients. Our extensive experience in meeting the stringent quality standards of global… ”
“ While we have already received approval for three products in China, our revenue aspirations extend beyond domestic markets ”
“ As multinational companies, we must not only localize our operations but also recognize and leverage the unique strengths and perspectives of our Chinese counterparts ”
“ True biotech isn't about managing portfolios like big pharma does. It's about addressing unmet medical needs where there's a clinical void that larger pharmaceutical companies haven't… ”
“ The transition to annual updates [of China's National Reimbursement Drug List] has greatly enhanced patient access to innovative drugs, reflecting positive changes in the regulatory landscape ”
“ The drug discovery industry is moving into a different, technology- and engineering-driven, phase. This favours China, which is very good at engineering and assembling novel molecules… ”
“ Cultural alignment and trust are paramount considerations when exploring collaborations or investments in the Chinese biotech sector ”
“ We need partners who understand that our mission is more than a business ”
